Guideline-directed heart failure therapy works, but the biggest hurdle is getting patients to actually take it and fresh results in Nature from the POLY-HF trial suggest a polypill approach could be the answer.
- Current GDMT for HF follows a quadruple approach of ARNIs, beta-blockers, MRAs, and SGLT2 inhibitors.
- POLY-HF combined three of these into one pill – a beta-blocker, an SGLT2 inhibitor, and an MRA.
Researchers then randomized 212 patients to receive either a single polypill or the same three medications taken separately once daily, finding that…
- The primary outcome of LVEF improved 3.3% more in the polypill group at six months.
- Patients on the polypill had a 60% lower rate of heart failure hospitalizations or ED visits.
- Adherence to therapy, confirmed through blood tests, was higher in the polypill group.
In the case of POLY-HF, the benefit parallels what we’ve seen in hypertension polypills – fewer pills meant better adherence, and better adherence meant patients actually received the therapeutic benefit these drugs are known to deliver.
All that said, while POLY-HF is an RCT published in Nature, it has some serious limitations that prevent it from being a paradigm-shifting study.
- With only 212 patients selected from 5000 reviewed records, this trial’s results are based on a highly curated study group.
- The primary endpoint of LVEF improvement only saw a 3.3% increase with polypills, which might be statistically significant, but likely isn’t clinically significant.
- Beyond that, some would argue that LVEF as an endpoint doesn’t say much about a patient’s health on its own.
The Takeaway
POLY-HF’s premise of making a patient’s life simpler is straightforward, and by its own design it backs up polypills for HF. However, it lacks the necessary “oomph” to really drive home whether or not an HF polypill should exist, so we’ll have to keep waiting for a bigger study to answer that.
